GLP-1 Market
LLY $1136.11 ▼ -0.2% NVO $42.53 ▼ -2.1% PFE $27.55 ▼ -0.6% VKTX $29.95 ▼ -5.0% KLRA $13.45 ▼ -2.2% GPCR $38.95 ▲ +1.3% RHHBY $54.90 ▲ +0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Ritlecitinib

Company
Massachusetts General Hospital
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
8 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

8 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for Ritlecitinib and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06373458

    Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

    Not yet reported Icahn School of Medicine at Mount Sinai 30 participants Est. completion 2028-01 1 site Stand-alone
    Other conditions: Keloid
    View official trial listing →
  • Recruiting NCT NCT06573593

    Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

    Second Affiliated Hospital, Zhejiang University, School of Medicine 150 participants Est. completion 2026-12-31 1 site
    Other conditions: Alopecia Areata, Janus Kinase Inhibitors
    View official trial listing →
  • Recruiting NCT NCT06873945

    A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

    Not yet reported Pfizer 1330 participants Est. completion 2028-03-19 146 sites Stand-alone
    Other conditions: Alopecia Areata
    View official trial listing →
  • Recruiting NCT NCT07029828

    A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

    Not yet reported Pfizer 140 participants Est. completion 2030-06-26 41 sites Stand-alone
    Other conditions: Severe Alopecia Areata
    View official trial listing →
  • Recruiting NCT NCT07152119

    A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.

    Pfizer 3000 participants Est. completion 2030-03-23 1 site
    Other conditions: Severe Alopecia Areata
    View official trial listing →
  • Recruiting NCT NCT07152626

    Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo

    Not yet reported Centre Hospitalier Universitaire de Nice 56 participants Est. completion 2029-06-01 5 sites Stand-alone
    Other conditions: Vitiligo
    View official trial listing →
  • Recruiting NCT NCT07219615

    A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

    Not yet reported Pfizer 200 participants Est. completion 2027-04-23 69 sites Stand-alone
    Other conditions: Chronic Spontaneous Urticaria
    View official trial listing →
  • Recruiting NCT NCT07733765

    A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

    Not yet reported Pfizer 336 participants Est. completion 2028-04-26 20 sites Stand-alone
    Other conditions: Alopecia Areata
    View official trial listing →
  • Completed NCT NCT03732807

    PF-06651600 for the Treatment of Alopecia Areata

    Not yet reported, Not yet reported Pfizer 718 participants Est. completion 2021-06-24 155 sites
    Other conditions: Alopecia Areata
    View official trial listing →
  • Completed NCT NCT04006457

    Long-Term PF-06651600 for the Treatment of Alopecia Areata

    Not yet reported Pfizer 1057 participants Est. completion 2026-02-26 144 sites
    Other conditions: Alopecia Areata
    View official trial listing →
  • Completed NCT NCT04413617

    TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

    Not yet reported Pfizer 460 participants Est. completion 2022-02-07 144 sites
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Terminated NCT NCT04517864

    PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

    Not yet reported Pfizer 71 participants Est. completion 2024-05-07 38 sites Stand-alone
    Other conditions: Alopecia Areata
    View official trial listing →
  • Completed NCT NCT04655040

    Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

    Not yet reported Pfizer 12 participants Est. completion 2021-03-05 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT05040295

    A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults

    Not yet reported Pfizer 12 participants Est. completion 2021-11-19 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT05097716

    Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

    Not yet reported Pfizer 12 participants Est. completion 2022-01-10 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT05128058

    A Target Occupancy Study With Ritlecitinib.

    Not yet reported Pfizer 16 participants Est. completion 2022-01-14 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Available NCT NCT05522556

    Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

    Pfizer
    Other conditions: Alopecia Areata
    View official trial listing →
  • Completed NCT NCT05549934

    Ritlecitinib for Cicatricial Alopecia

    Not yet reported Emma Guttman 50 participants Est. completion 2025-03-20 1 site Stand-alone
    Other conditions: Cicatricial Alopecia
    View official trial listing →
  • Completed NCT NCT05583526

    A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

    Not yet reported Pfizer 607 participants Est. completion 2026-02-05 115 sites Stand-alone
    Other conditions: Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
    View official trial listing →
  • Completed NCT NCT05636293

    Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

    Not yet reported Massachusetts General Hospital 62 participants Est. completion 2026-04-09 1 site
    Other conditions: Celiac Disease
    View official trial listing →
  • Completed NCT NCT05650333

    A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

    Not yet reported Pfizer 15 participants Est. completion 2023-08-11 9 sites Stand-alone
    Other conditions: Alopecia Areata
    View official trial listing →
  • Active, not recruiting NCT NCT05743244

    Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 78 participants Est. completion 2027-10-30 30 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT05852340

    A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

    Not yet reported Pfizer 12 participants Est. completion 2023-07-24 1 site
    Other conditions: Healthy Volunteers, Adult, Pharmacokinetics
    View official trial listing →
  • Terminated NCT NCT05879458

    Ritlecitinib in CTCL

    Not yet reported Icahn School of Medicine at Mount Sinai 7 participants Est. completion 2025-06-25 1 site Stand-alone
    Other conditions: CTCL, Mycosis Fungoides, Sezary Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT06072183

    A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

    Not yet reported Pfizer 1571 participants Est. completion 2027-07-30 229 sites Stand-alone
    Other conditions: Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
    View official trial listing →
  • Active, not recruiting NCT NCT06163326

    A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

    Not yet reported Pfizer 394 participants Est. completion 2027-03-31 73 sites Stand-alone
    Other conditions: Vitiligo
    View official trial listing →
  • Completed NCT NCT06172348

    A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

    Not yet reported Pfizer 12 participants Est. completion 2024-03-28 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Active, not recruiting NCT NCT06279221

    Litfulo Capsules Special Investigation

    Pfizer 664 participants Est. completion 2030-01-18 1 site
    Other conditions: Alopecia Areata
    View official trial listing →
  • Completed NCT NCT06369454

    A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

    Not yet reported Pfizer 12 participants Est. completion 2024-07-31 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Active, not recruiting NCT NCT06531109

    Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

    Pfizer 450 participants Est. completion 2028-04-15 70 sites
    Other conditions: Alopecia Areata
    View official trial listing →
  • Withdrawn NCT NCT06795373

    Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria

    Not yet reported Ahuva D Cices Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Chronic Spontaneous Urticaria, CSU
    View official trial listing →
  • Active, not recruiting NCT NCT07029711

    A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

    Not yet reported Pfizer 208 participants Est. completion 2027-01-06 83 sites Stand-alone
    Other conditions: Severe Alopecia Areata
    View official trial listing →
  • Completed NCT NCT07200128

    A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

    Pfizer 123 participants Est. completion 2025-05-30 1 site
    Other conditions: Severe Alopecia Areata
    View official trial listing →
  • Completed NCT NCT07226531

    Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

    Pfizer 300 participants Est. completion 2026-03-06 1 site
    Other conditions: Alopecia Areata
    View official trial listing →
  • Active, not recruiting NCT NCT07228390

    A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

    Not yet reported Pfizer 128 participants Est. completion 2027-01-05 67 sites Stand-alone
    Other conditions: Hidradenitis Suppurativa
    View official trial listing →
  • Not yet recruiting NCT NCT07821216

    Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data

    Pfizer 7500 participants Est. completion 2027-04-20
    Other conditions: Alopecia Areata
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Ritlecitinib, Litfulo

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.